We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should Value Investors Consider Sanofi (SNY) Stock Now?
Read MoreHide Full Article
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put Sanofi (SNY - Free Report) stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:
PE Ratio
A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.
On this front, Sanofi has a trailing twelve months PE ratio of 12.95, as you can see in the chart below:
This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 stands at about 14.25. If we focus on the long-term PE trend, Sanofi’s current PE level puts it below its midpoint of $13.64 over the past five years. Moreover, the current level stands well below the highs for the stock, suggesting that it can be a solid entry point.
Further, the stock’s PE also compares favorably with the Zacks Medical sector’s trailing twelve months PE ratio, which stands at 20.38. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.
We should also point out that Sanofi has a forward PE ratio (price relative to this year’s earnings) of just 12.7, so it is fair to say that a slightly more value-oriented path may be ahead for Sanofi stock in the near term too.
P/S Ratio
Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.
Right now, Sanofi has a P/S ratio of about 2.58. This is a bit lower than the S&P 500 average, which comes in at 3.19x right now. Also, as we can see in the chart below, this is well below the highs for this stock in particular over the past few years.
If anything, this suggests some level of undervalued trading—at least compared to historical norms.
Broad Value Outlook
In aggregate, Sanofi currently has a Value Score of A, putting it into the top 20% of all stocks we cover from this look. This makes Sanofi a solid choice for value investors, and some of its other key metrics make this pretty clear too.
For example, the PEG ratio for Sanofi is just 1.89, a level that is far lower than the industry average of 2.04. The PEG ratio is a modified PE ratio that takes into account the stock’s earnings growth rate. Clearly, SNY is a solid choice on the value front from multiple angles.
What About the Stock Overall?
Though Sanofi might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth Score of C and a Momentum Score of F. This gives SNY a Zacks VGM score — or its overarching fundamental grade — of B. (You can read more about the Zacks Style Scores here >>)
Meanwhile, the company’s recent earnings estimates have been robust at best. The current year has seen three estimates go higher in the past sixty days compared to one lower, while the next year estimate has seen four up and none down in the same time period.
This has had just a small impact on the consensus estimate though as the current quarter consensus estimate has risen by 0.6% in the past two months, while the full year estimate has inched lower by 2%. You can see the consensus estimate trend and recent price action for the stock in the chart below:
This somewhat bullish trend is why the stock has just a Zacks Rank #2 (Buy) and why we are looking for outperformance from the company in the near term.
Bottom Line
Sanofi is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. Further, a strong industry rank (among Top 16% of more than 250 industries) instills our confidence. However, over the past two years, the Zacks Large Cap Pharmaceuticals industry has clearly underperformed the broader market, as you can see below:
So, value investors might want to wait for analyst sentiment to turn around in this name first, but once that happens, this stock could be a compelling pick.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Should Value Investors Consider Sanofi (SNY) Stock Now?
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put Sanofi (SNY - Free Report) stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:
PE Ratio
A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.
On this front, Sanofi has a trailing twelve months PE ratio of 12.95, as you can see in the chart below:
This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 stands at about 14.25. If we focus on the long-term PE trend, Sanofi’s current PE level puts it below its midpoint of $13.64 over the past five years. Moreover, the current level stands well below the highs for the stock, suggesting that it can be a solid entry point.
Further, the stock’s PE also compares favorably with the Zacks Medical sector’s trailing twelve months PE ratio, which stands at 20.38. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.
We should also point out that Sanofi has a forward PE ratio (price relative to this year’s earnings) of just 12.7, so it is fair to say that a slightly more value-oriented path may be ahead for Sanofi stock in the near term too.
P/S Ratio
Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.
Right now, Sanofi has a P/S ratio of about 2.58. This is a bit lower than the S&P 500 average, which comes in at 3.19x right now. Also, as we can see in the chart below, this is well below the highs for this stock in particular over the past few years.
If anything, this suggests some level of undervalued trading—at least compared to historical norms.
Broad Value Outlook
In aggregate, Sanofi currently has a Value Score of A, putting it into the top 20% of all stocks we cover from this look. This makes Sanofi a solid choice for value investors, and some of its other key metrics make this pretty clear too.
For example, the PEG ratio for Sanofi is just 1.89, a level that is far lower than the industry average of 2.04. The PEG ratio is a modified PE ratio that takes into account the stock’s earnings growth rate. Clearly, SNY is a solid choice on the value front from multiple angles.
What About the Stock Overall?
Though Sanofi might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth Score of C and a Momentum Score of F. This gives SNY a Zacks VGM score — or its overarching fundamental grade — of B. (You can read more about the Zacks Style Scores here >>)
Meanwhile, the company’s recent earnings estimates have been robust at best. The current year has seen three estimates go higher in the past sixty days compared to one lower, while the next year estimate has seen four up and none down in the same time period.
This has had just a small impact on the consensus estimate though as the current quarter consensus estimate has risen by 0.6% in the past two months, while the full year estimate has inched lower by 2%. You can see the consensus estimate trend and recent price action for the stock in the chart below:
Sanofi Price and Consensus
Sanofi price-consensus-chart | Sanofi Quote
This somewhat bullish trend is why the stock has just a Zacks Rank #2 (Buy) and why we are looking for outperformance from the company in the near term.
Bottom Line
Sanofi is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. Further, a strong industry rank (among Top 16% of more than 250 industries) instills our confidence. However, over the past two years, the Zacks Large Cap Pharmaceuticals industry has clearly underperformed the broader market, as you can see below:
So, value investors might want to wait for analyst sentiment to turn around in this name first, but once that happens, this stock could be a compelling pick.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>